NCT00385489已完成1 期
Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of LXR-623 Administered Orally to Healthy Japanese Male Subjects.
Wyeth is now a wholly owned subsidiary of Pfizer1 个研究点 分布在 1 个国家开始时间: 2006年8月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 1
- 主要终点
- Safety
研究概览
简要总结
The purpose of this study is to evaluate the safety of LXR-623 in healthy Japanese subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 20 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy, Japanese Males aged 20-45 years
排除标准
- •A history or active presence of clinically important medical disease
结局指标
主要结局
Safety
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Study Evaluating LXR-623 in Healthy SubjectsHealthyNCT00366522Wyeth is now a wholly owned subsidiary of Pfizer
已完成
1 期
A Study of LY3471851 in Healthy ParticipantsHealthyNCT04133116Nektar Therapeutics36
已完成
1 期
A Single Dose Study Of The Safety And Investigational Product Level Measurement In Healthy SubjectsHealthyNCT01284036Ablynx, a Sanofi company63
已完成
1 期
Study Evaluating the Safety of FXR-450 in Healthy SubjectsHealthyNCT00499629Wyeth is now a wholly owned subsidiary of Pfizer64
终止
1 期
Study Evaluating FXR-450 in Healthy Japanese MenHealthyNCT00509756Wyeth is now a wholly owned subsidiary of Pfizer56